Detalhe da pesquisa
1.
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Cancer
; 128(17): 3185-3195, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737639
2.
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Neuro Oncol
; 25(6): 1113-1122, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455228
3.
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.
Nat Commun
; 14(1): 1359, 2023 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36914652
4.
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
Eur J Haematol
; 88(5): 406-15, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22309072
5.
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma.
Neurooncol Adv
; 4(1): vdac146, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382109
6.
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Clin Cancer Res
; 27(2): 438-446, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046517
7.
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Eur J Cancer
; 146: 115-124, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33601323
8.
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
J Neurooncol
; 96(3): 393-402, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19688297
9.
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Lancet Haematol
; 7(9): e649-e659, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758434
10.
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 139: 135-148, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32992153
11.
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Clin Cancer Res
; 14(9): 2717-25, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18451237
12.
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
N Engl J Med
; 347(7): 481-7, 2002 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12181402
13.
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
J Clin Oncol
; 23(4): 866-73, 2005 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15681532
14.
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
Cancer Chemother Pharmacol
; 53(5): 433-8, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15132131
15.
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
J Clin Oncol
; 27(19): 3141-7, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19451435
16.
Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.
Curr Clin Pharmacol
; 3(3): 198-203, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18781906
17.
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
J Clin Oncol
; 26(4): 620-5, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18235121
18.
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
Blood
; 109(1): 61-4, 2007 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16960151
19.
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
J Clin Oncol
; 24(7): 1195-203, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16505440